Summary Co-expression of macrophage colony-stimulating factor (M-CSF) and its receptor (c-fms) is often found in ovarian epithelial carcinoma, suggesting the existence of autocrine regulation of cell growth by M-CSF. To block this autocrine loop, we have developed hammerhead ribozymes against c-fms mRNA. As target sites of the ribozyme, we chose the GUC sequence in codon 18 and codon 27 of cfms mRNA. Two kinds of ribozymes were able to cleave an artificial c-fms RNA substrate in a cell-free system, although the ribozyme against codon 18 was much more efficient than that against codon 27. We next constructed an expression vector carrying a ribozyme sequence that targeted the GUC sequence in codon 18 of c-fms mRNA. It was introduced into TYK-nu cells that expressed M-CSF and its receptor. Its transfectant showed a reduced growth potential. The expression levels of c-fms protein and mRNA in the transfectant were clearly decreased with the expression of ribozyme RNA compared with that of an untransfected control or a transfectant with the vector without the ribozyme sequence. These results suggest that the ribozyme against GUC in codon 18 of c-fms mRNA is a promising tool for blocking the autocrine loop of M-CSF in ovarian epithelial carcinoma.
Ovarian epithelial carcinoma is a rather rare cancer in Japan, but the difficulty in diagnosis at an early clinical stage results in its being one of the most deadly cancers in Japanese women. Some genetic alterations, such as activation of proto-oncogenes, loss of tumour-suppressor function and autocrine growth stimulation by peptide growth factors, may be implicated in the development of ovarian epithelial cancer, although detailed molecular mechanisms of ovarian carcinogenesis have never been elucidated . Abnormal expression of proto-oncogenes, such as HER-2/neu, c-fins, c-fos, c-myc, n-myc and c-H-ras, has been reported in ovarian epithelial carcinoma (Tyson et al, 1991; Bast et al, 1993) .
C-fins is one of the oncogenes of which abnormal expression is frequently found in ovarian epithelial carcinoma. It encodes a transmembrane tyrosine kinase receptor for the macrophage colony-stimulating factor (M-CSF). As a receptor of M-CSF, this is an essential gene for the development of macrophages and other tissues, such as placenta. Recently, attention has been focused on the association of the gene with the carcinogenesis of nonhaematopoietic tissues. To date, a predominant number of breast, ovarian and endometrial carcinomas are known to express the cfins gene (Kacinski et al, 1990; Kacinski et al, 1991; . The expression level of c-fins transcripts in ovarian epithelial carcinoma has been described as correlating strongly with high-grade histology, advanced clinical presentations and poor outcome of the patients (Kacinski, 1995) .
M-CSF is not only a stimulator of macrophage differentiation but also a stimulator of osteoclast progenitor cell differentiation (Pollard et al, 1991) and placental development (Pollard et al, 1987) . It is produced by fibroblasts and endothelial cells. In addition, some kinds of carcinoma, such as ovarian epithelial carcinomas, endometrial carcinomas and mammary carcinomas, have been shown to produce M-CSF (Baiocchi et al, 1991 ). An abnormally high level of M-CSF is found in the sera of ovarian epithelial carcinoma patients with active disease, and the usefulness of M-CSF as a tumour marker in ovarian epithelial carcinoma has been proposed (Kacinski et al, 1989; Suzuki et al, 1993) .
It has been shown that recombinant human M-CSF exposure can lead to the phosphorylation on tyrosine of a variety of proteins in c-fins-positive and M-CSF-negative carcinoma cell lines (Kacinski et al, 1991) , and that M-CSF can accelerate the proliferation of c-fins-positive carcinoma cells (Croxtall et al, 1992) . More recently, it has been demonstrated that M-CSF treatment could enhance the invasiveness of cancer cells that express c-fins (Filderman et al, 1992) . These results imply that M-CSF can lead c-fins-positive cancer cells to a more malignant phenotype. The fact that a predominant number of ovarian epithelial carcinoma tissues co-express M-CSF and its receptor (Baiocchi et al, 1991; Kommoss et al, 1994) suggests that autocrine/paracrine regulation of M-CSF exists in ovarian epithelial carcinoma cells and leads them to a more malignant phenotype.
One means of blocking the autocrine loop is to use a hammerhead ribozyme, which intercepts the mRNA of c-fins. The hammerhead ribozymes contain two functional modules, i.e. a catalytic core that cleaves the target RNA and the flanking regions that, by virtue of complementarity, direct the ribozyme core to a specific site. By exploiting the flexibility of these two modular functions, it is possible to design a ribozyme to cleave specifically any target RNA molecules (Cech and Bass, 1986; Rossi et al, 1991; Dorai et al, 1994) . We have studied the possibility of hammerhead ribozymes as a therapeutic tool against ovarian epithelial carcinoma cells. RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR) for c-fms and M-CSF Total RNA was extracted using Isogene (NipponGene, Toyama, Japan). Ovarian carcinoma cell lines were plated on a 10 cm culture plate. At 48 h after seeding, the total RNA was extracted. Tissue samples (approximately 100 mg) were suspended in 1 ml of Isogene and then homogenized. All procedures for extraction were according to the manufacturer's protocol.
The upstream primer (5'-AACAAGACAAACAGCCAG) was designed in the 5'-untranslated sequence of c-fins mRNA, and the downstream primer (5'-AGGGGGTCTCCAGGCTCAGT) was designed in the sequence of the open reading frame. The corresponding sites of the primers, target sites of the ribozymes in c-fins mRNA and the structure of the c-fins gene are shown in Figure 1 . The length of the PCR product was 406 bases. The primers for M-CSF and G3PDH were derived from the work of other investigators (Kawasaki et al, 1985; Adcock et al, 1994 ) (M-CSF: upstream primer, 5'-ACGACATGGCTGGGCTCCCT and downstream primer, 5'-TTCTCCAGCAACTGGAGAGGTG. G3PDH: upstream primer, 5'-TGAAGGTCGGAGTCAACGGAThTTGGT and downstream primer, 5'-CATGTGGGCCATGAGGTCCAC-CAC). The PCR product of M-CSF or G3PDH was 407 or 572 bases long respectively. Complementary DNA was synthesized using Moloney murine leukaemia virus reverse transcriptase (Takara Shuzo, Kyoto, Japan) with a random hexamer. A 5-gl aliquot of cDNA product was submitted to PCR reaction.
PCR was carried out under the following conditions: 35 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 1.5 min. PCR products were electrophoresed in 1.5% agarose gel and analysed by sequence reaction.
Cloning of PCR products and sequencing
The RT-PCR product of c-fins from placental RNA was extracted from the agarose gel and purified using a Gene Clean II kit (Bio 101, LaJolla, CA, USA). The DNA fragment was ligated directly to PCR TI-vector (Invitrogen, San Diego, CA, USA). After transformation of E. coli, colonies were selected and screened. Plasmid DNA was prepared using a Megaprep kit (Qiagen, Chatsworth, CA, USA). A double-strand sequence was performed using a CircumVent thermal cycle dideoxy DNA sequencing kit (New England Biolabs, Beverly, MA, USA) and 35S-dATP (Du Pont, Wilmington, DE, USA). At least ten colonies were screened.
In vitro transcription of RNA from plasmid template or synthetic DNA template Transcription of RNA from plasmid templates that contained SP6 RNA polymerase promoter was carried out using MAXscript In Vitro transcription kits (Ambion, Austin, TX, USA). The pCRII containing the c-fins PCR product was digested with XhoI. The transcription reaction mixture contained 1 jig of linearized plasmid DNA, 0.5 U ml-' SP6 RNA polymerase, 40 mM Tris-HCI, pH 7.5, 6 mm magnesium chloride, 10 mm sodium chloride, 2 mM spermidine, 10 mM dithiothreitol, 0.5 mM ATP, GTP and UTP, 0.1 mM CTP, 50 jCi of [a-32P]CTP (specific activity 800 Ci mmol-1) (Du Pont) and 1 U ml-1 recombinant ribonuclease inhibitor in 100 g1 of British Journal of Cancer (1997) 76(8), [977] [978] [979] [980] [981] [982] Ribozyme targeting c-fms in ovarian carcinoma 979
In vitro cleavage reaction
The ribozyme and substrate RNA were mixed in a I10-gl reaction volume containing 50 mm Tris-HCl, pH 7.5, and 1 mM EDTA. The mixture was heated at 95°C for 2 min, quick cooled on ice, magne-130 kDa sium chloride was added to a final concentration of 10 mM and then it was incubated at 370C for various times. The reactions were stopped by the addition of an equal volume of stop solution (95%   407 bp formamide, 25 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol) and heated at 650C for 5 min. The reaction mixture was electrophoresed in a 6% polyacrylamide-7 M urea gel in Trisborate EDTA buffer. The reaction was analysed by autoradiography. volume. The reaction was carried out at 370C for 1 h. The reaction mixture was treated with RNAase-free DNAase followed by phenol-chloroform extraction and ammonium acetate ethanol precipitation.
To synthesize the c-fins ribozymes against the GUC of codon 18 and codon 27, two sets of primers were used. To synthesize the template of the ribozyme against codon 18 (18 ribozyme), one primer containing the bacteriophage T`7 RNA polymerase promoter sequence (5'-GGATCCTAATACGACTCACTATAG-GGATTCCCTCTGATGAG) and the other one (5'-TTGGCATGGT-TTCGTCCTCACGGACTCATCAGAGGGAAT) were designed. To synthesize the template of the ribozyme against codon 27 (27 ribozyme), one primer was designed 5'-GGATCCTAATAC-GACTCACTATAGGCCAGCTCGGGCTGATG and the other was designed 5'-AGCCCAGTGTTTCGTCCTCTCGGACTCATCAG-CCCGAGC. The primers were mixed to form a hemiduplex, and the PCR amplification was performed. The transcription of RNA from the synthetic DNA template was carried out under similar conditions except that we used the same amount of cold rNTPs without [a-32P] CTP. The synthetic DNA template concentration in the reaction mixture was 0.02 mg ml-'.
Construction of eukaryotic expression vector of ribozyme and transfection
The 18 ribozyme used for transfection study was designed differently from that used in the cell-free system. Two single-stranded oligodeoxynucleotides were synthesized such that the 45-bp ribozyme contained flanking Sall and XhoI restriction sites on both ends (5'-pTCGACGGATTCCCTCTGATGAGTCCGTGAG-GACGAAACCATGCCA and 5'-pAGCTTGGCATGG'TTC-GTCCTCACGGACTCATCAGAGGGAATCCG). They were 5' phosphorylated by T4 polynucleotide kinase (New England Biolabs), annealed and cloned into the pH,APr-l-neo (Gunning et al, 1987) . Of this mammalian expression vector, the transcription of a cloned gene is driven by the human ,-actin promoter and augmented by the enhancer element existing in the first intervening sequence of the P-actin gene. The sequences following the initiation codon of translation of human 3-actin are replaced by the polylinker sequence for HindIII, Sall and BamHl restriction enzymes. The sequence and orientation of the ribozyme in the vector were confirmed by DNA sequencing with a sequence primer (5'-GACCAGTGThTTGCCTlTTA-3'). It was designed from the sequences in the 5'-untranslated region of ,-actin. The constructed vector was designated pH,BAPr--neo-1 8RZ.
Lipofection of TYK-nu cells with pH3APr-l-neo-18RZ or pH,APr-l-neo was done according to the protocol that the manufacturer (Gibco-BRL) recommended. In brief, approximately 5 x 104 cells were transfected with 10 gg of the vector DNA that had been complexed with 50 gl of lipofectin (Gibco-BRL). Three days after the transfection, G418 was added to the medium to a flnal concentration of 1 mg ml. The transfected cells had been exposed to G418 for 4 weeks. In total, 12 clones or 26 clones were obtained from transfectants with pHPAPr-l-neo-18RZ or pHbAPr--neo respectively. The pooled clones of each transfectant were named TYK-nu-I8RZ and TYK-nu-pHAP.
RT-PCR and Southern blot analysis for ribozyme expression
Total RNA was extracted from the transfectants and parental TYK-nu cells using Isogene (Nippongene). Total RNA (500 ng) from each transfectant was reverse-transcribed with a random hexamer, followed by PCR using two primers: 5'-AGCACA-GAGCCTCGCCTTT (from ,B-actin 5'-untranslated region) and 5'-TGGATCCCTCGAAGCFT (from plasmid polylinker The number of cells in the dish was counted at 1, 3 and 5 days, and the growth rate was expressed as a number relative to the control. The experiment was carried out in triplicate. Results obtained were evaluated by Student's t-test.
RESULTS
First, we sought to determine whether the c-fms protein and the M-CSF transcript are in fact expressed in ovarian carcinoma cell lines and carcinoma tissues. As a positive control, we used human placental tissue and BeWo cells. Because ribozymes recognize a GUC sequence and cleave it most efficiently, attempts were made to determine whether a GUC sequence is located within any critical region on c-fins mRNA. There are 32 GUC sequences in the coding regions, three GUC sequences in the 5'-untranslated regions and ten GUC sequences in the 3'-untranslated regions. Because cleavage within the open reading frame of c-fins mRNA by ribozymes will be able to destroy the function of mRNA completely, and the distal region of the open reading frame is likely to be exposed at the outer surface of the three-dimensional structure of the mRNA, we chose the GUC sequences of codons 18 and 27 as target sites of ribozymes. Two kinds of hammerhead ribozymes were designed to target the GUC sequence in these codons of c-fins mRNA, based on the model proposed by Haseloff and Gerlach (1988) . The sequences of the target site and the hammerhead ribozymes are shown in Figure  4 . Oligonucleotides encoding the catalytic core of the ribozyme, the flanking sequences complementary to the target sequence and a T7 RNA polymerase promoter were synthesized. After anealing a pair of deoxyoligonucleotides containing the T7 promoter sequence and the ribozyme sequence, a double-stranded synthetic substrate was made by a PCR method. It was transcribed with T7 RNA polymerase to generate 44-base ribozymes, according to published procedures (Milligan et al, 1987) .
To create a synthetic c-fins substrate RNA, a fairly large region encompassing the target site, which could thus mimic the secondary structures in the native mRNA, was selected between the 5'-untranslated region and the codon 91 of c-fins mRNA. Sequence analysis of the cloned PCR product indicated that there were no mutations in the c-fins mRNA in the region amplified, which included the target sites. Transcribing the sense RNA construct by SP6 RNA polymerase yielded a 525-base labelled RNA substrate. This substrate and the ribozymes were mixed at a molar ratio of 1:5, and a cleavage reaction was then observed in the cell-free system. As shown in Figure 5 , the hammerhead ribozymes against codon 18 and 27 cleaved the 525-base c-fins substrate into 267-and 258-base fragments and 296-and 219-base fragments respectively. The cleaved fragments were the correct sizes, as predicted from the location of the cleavage site of the (Figure 6 ).
Next, we studied the growth potential of the transfectants. The proliferation rates of transfectants and parental TYK-nu cells are shown in Figure 7 . In order to ignore the influence of exogenous M-CSF, the growth potential was evaluated under serum-free conditions. The transfectant with pH,BAPr-l-neo-18RZ grew more slowly than parental TYK-nu cells and TYK-nu-PH cells. The difference in the growth rate was statistically significant at the fifth day [P < 
DISCUSSION
To date, c-fins is among the most significant oncogenes involved in ovarian carcinogenesis (Gallion and Bast, 1993) . Abnormal expression of H-ras, K-ras, C-myc or N-myc was found in some ovarian epithelial carcinomas, but the frequency of these abnormalities was much less than that of c-fins (Roussel, 1994) . C-erbB-2 is a counterpart, of which abnormal expression is often found in ovarian carcinoma. The frequency of the expression or the gene amplification has been reported in 86% or 30% of ovarian epithelial carcinomas respectively (Tyson et al, 1991) . However, the evidence of autocrine and/or paracrine regulations through c-erbB-2 has never been demonstrated in ovarian epithelial carcinoma. In the present study, we found that the c-fins as well as the M-CSF transcript and/or protein was expressed in a predominant number of ovarian epithelial carcinoma tissues and cell lines. Our observation was largely based on the RT-PCR technique, and positive RT-PCR does not mean substantial existence of proteins. Frequent co-expression of these transcripts in ovarian carcinomas, however, has been reported by other investigators (Baiocchi et al, 1991; Bauknecht et al, 1994) . Taken together, it is conceivable that autocrine regulation of M-CSF may exist in some ovarian epithelial carcinomas. In addition, M-CSF can be secreted by the surrounding stromal cells and endothelial cells. It can affect ovarian carcinoma cells that express the c-fms protein by a paracrine mechanism. Female reproductive tissues are the major sites at which M-CSF is produced. During pregnancy, synthesis of M-CSF markedly increases at the epithelium of the oviducts and the endometrium of the uterus (Arceci et al, 1989) . Normal ovarian epithelium expresses M-CSF (Lidor et al, 1990 ). In such an environment, acquisition of c-fins expression of ovarian epithelial cells can establish autocrine/paracrine stimulation by M-CSF and may consequently lead the cells to malignant transformation.
Because the target site of ribozymes must be sufficiently exposed on the outer surface of the three-dimensional structure of the mRNA for the ribozyme to access (Tiara and Nishizawa, 1992), we first studied which target site is more effective for ribozyme cleavage, the GUC sequence of codon 18 or that of codon 27 c-fins inRNA. An in vitro cleavage study showed that the ribozyme against codon 18 was much more efficient than that against codon 27. Therefore, we chose the 18 ribozyme for the transfection study.
We could successfully reduce the expression level of the c-fms protein in TYK-nu cells by the introduction of the 18 ribozyme. Reduced expression of the c-fms protein resulted in the decreased growth potential of the cells. This result strongly implicates the pathological role of this oncogene in the development of ovarian cancer. We have shown that the GUC sequence of codon 18 is a good target site of the ribozyme, but the 18 ribozyme could not totally extinguish the expression of c-fms. This may be attributed to further difficulty of the ribozyme in accessing the target site. To search for better target sites, a further study is in progress at our laboratory.
